Canakinumab
Anti-IL-1β monoclonal antibody
- Response rate
- 45% complete (Phase III); >94% disease control (long-term)
- Onset
- Days–weeks
- Route
- SC 150mg every 4–8 weeks
- Line
- 1st
- IgM effect
- N/A
Evidence summary
Selectively neutralises IL-1β with a long half-life allowing monthly dosing. The CLUSTER Phase III RCT (De Benedetti 2018) showed 45% complete response vs 8% placebo in TRAPS. The 72-week extension demonstrated >94% achieving no/minimal disease activity with sustained treatment. FDA/EMA approved for TRAPS. No patients on canakinumab developed AA amyloidosis in the Eurofever registry.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-1β | Key effector cytokine | Elevated | established |